Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental syndromes diagnostically characterized by deficits in social communication and social interaction and repetitive, inflexible patterns of behaviors, interests, and thoughts. ASD affects people worldwide, irrespective of race, ethnicity, or socio-economic status, with debilitating effects on employment and interpersonal relationships. Though the atypical antipsychotics aripiprazole and risperidone are approved to treat irritability associated with ASD, these drugs may elicit treatment-limiting adverse effects, such as suicidal ideation, sedation, diarrhea, loss of appetite, dizziness, and weight gain. However, there are no approved pharmacotherapeutics for global symptoms of ASD, and better treatments are needed. Drugs with pro-social effects, such as 3,4-methylenedioxymethamphetamine (MDMA) and its analogues, may be beneficial here, as social anxiety and social avoidance are major complications of ASD that adversely impact the quality of life for sufferers and caregivers. This review describes the complex pharmacology of methylenedioxy amphetamine analogues (hereafter referred to as MDXX drugs), focusing on MDMA and 3,4-methylenedioxy-N-methyl-α-ethylphenylethylamine (MBDB) and how they may help treat ASD. Specifically, we address the roles of various drug-binding sites, metabolic enzymes, and chemical structure-activity relationships that mediate these substances' pharmacological and toxicological effects. Throughout the review, we emphasize the distinct profiles of individual stereoisomers of the MDXX drugs and how combining these enantiomers as racemic mixtures may explain the complexity of drug effects on behavior and physiology. We propose that the MDXX drugs represent a fruitful chemical space for developing clinically effective and relatively safer molecules and formulations for treating ASD.
Get full access to this article
View all access options for this article.
References
1.
HenningfieldJE, AshworthJ, HealDJ, et al.Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. J Psychopharmacol, 2023; 37(1):33–44; doi: 10.1177/02698811221140004
2.
HenningfieldJE, CoeMA, GriffithsRR, et al.Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology, 2022; 218:109220; doi: 10.1016/j.neuropharm.2022.109220
JohnsonMW, GriffithsRR, HendricksPS, et al.The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 2018; 142:143–166; doi: 10.1016/j.neuropharm.2018.05.012
5.
HealthTLG. Mental health matters. Lancet Global Health, 2020; 8(11):e1352; doi: 10.1016/s2214-109x(20)30432-0
UN, Ki-moonB. Promoting the Autism Advantage on World Autism Awareness Day | DESANews—United Nations Department of Economic and Social Affairs. n.d. Available from: https://press.un.org/en/2015/sgsm16639.doc.htm [Last accessed: December19, 2022].
10.
RoggeN, JanssenJ. The economic costs of autism spectrum disorder: A literature review. J Autism Dev Disord, 2019; 49(7):2873–2900; doi: 10.1007/s10803-019-04014-z.
11.
FuJM, SatterstromFK, PengM, et al.Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. Nat Genet, 2022; 54(9):1320–1331; doi: 10.1038/s41588-022-01104-0
12.
GuangS, PangN, DengX, et al.Synaptopathology involved in autism spectrum disorder. Front Cell Neurosci, 2018; 12:470; doi: 10.3389/fncel.2018.00470
13.
BoeckersTM, BockmannJ, KreutzMR, et al.ProSAP/Shank proteins—A family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem, 2002; 81(5):903–910; doi: 10.1046/j.1471-4159.2002.00931.x
14.
DurandCM, BetancurC, BoeckersTM, et al.Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet, 2007; 39(1):25–27; doi: 10.1038/ng1933
15.
PeñagarikanoO, GeschwindDH. What does CNTNAP2 reveal about autism spectrum disorder?. Trends Mol Med, 2012; 18(3):156–163; doi: 10.1016/j.molmed.2012.01.003
16.
LazaroMT, TaxidisJ, ShumanT, et al.Reduced prefrontal synaptic connectivity and disturbed oscillatory population dynamics in the CNTNAP2 model of autism. Cell Rep, 2019; 27(9):2567–2578.e6; doi: 10.1016/j.celrep.2019.05.006
17.
AndersonGR, GalfinT, XuW, et al.Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development. Proc Natl Acad Sci U S A, 2012; 109(44):18120–18125; doi: 10.1073/pnas.1216398109.
18.
SchainRJ, FreedmanDX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatrics, 1961; 58(3):315–320; doi: 10.1016/s0022-3476(61)80261-8
19.
GabrieleS, SaccoR, PersicoAM. Blood serotonin levels in autism spectrum disorder: A systematic review and meta-analysis. Eur Neuropsychopharm, 2014; 24(6):919–929; doi: 10.1016/j.euroneuro.2014.02.004
20.
D'EufemiaP, FinocchiaroR, CelliM, et al.Low serum tryptophan to large neutral amino acids ratio in idiopathic infantile autism. Biomed Pharmacother, 1995; 49(6):288–292; doi: 10.1016/0753-3322(96)82645-x
21.
McDougleC, NaylorST, CohenDJ, et al.Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry, 1996; 53(11):993–1000; doi: 10.1001/archpsyc.1996.01830110029004
22.
NakamuraK, SekineY, OuchiY, et al.Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry, 2010; 67(1):59–68; doi: 10.1001/archgenpsychiatry.2009.137
23.
AdamsenD, RamaekersV, HoHT, et al.Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism, 2014; 5(1):43; doi: 10.1186/2040-2392-5-43
24.
MurphyDGM, DalyE, SchmitzN, et al.Cortical serotonin 5-HT 2A receptor binding and social communication in adults with Aspergers syndrome: An in vivo SPECT study. Am J Psychiatry, 2006; 163(5):934–936; doi: 10.1176/ajp.2006.163.5.934
25.
LiX, ZhangK, HeX, et al.Structural, functional, and molecular imaging of autism spectrum disorder. Neurosci Bull, 2021; 37(7):1051–1071; doi: 10.1007/s12264-021-00673-0
26.
LefevreA, RichardN, MottoleseR, et al.An association between serotonin 1A receptor, gray matter volume, and sociability in healthy subjects and in autism spectrum disorder. Autism Res, 2020; 13(11):1843–1855; doi: 10.1002/aur.2360
BrandenburgC, BlattGJ. Differential serotonin transporter (5-HTT) and 5-HT2 receptor density in limbic and neocortical areas of adults and children with autism spectrum disorders: Implications for selective serotonin reuptake inhibitor efficacy. J Neurochem, 2019; 151(5):642–655; doi: 10.1111/jnc.14832
29.
VergneD, AntonR. Aripiprazole: A drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord Drug Targets, 2010; 9(1):50–54; doi: 10.2174/187152710790966731
NaranjoC, ShulginAT, SargentT. Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Pharmacology, 1967; 17(4):359–364; doi: 10.1159/000137100
GlennonRA, TitelerM, McKenneyJD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci, 1984; 35(25):2505–2511; doi: 10.1016/0024-3205(84)90436-3
34.
NicholsDE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. J Psychoactive Drugs, 1986; 18(4):305–313; doi: 10.1080/02791072.1986.10472362
35.
NicholsDE, LloydDH, HoffmanAJ, et al.Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes. J Med Chem, 1982; 25(5):530–535; doi: 10.1021/jm00347a010
36.
BattagliaG, BrooksBP, KulsakdinunC, et al.Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol, 1988; 149(1–2):159–163; doi: 10.1016/0014-2999(88)90056-8
37.
BattagliaG, SouzaEBD. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: Selective effects on serotonergic systems. Nida Res Monogr, 1989; 94:240–258
38.
RudnickG, WallSC. The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A, 1992; 89(5):1817–1821; doi: 10.1073/pnas.89.5.1817
39.
SchmidtCJ, TaylorVL. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol, 1987; 36(23):4095–4102; doi: 10.1016/0006-2952(87)90566-1
40.
RothmanRB, BaumannMH, DerschCM, et al.Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 2001; 39(1):32–41; doi: 10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3
41.
AcquasE, MarrocuP, PisanuA, et al.Intravenous administration of ecstasy (3,4-methylendioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol, 2001; 418(3):207–211; doi: 10.1016/s0014-2999(01)00937-2
42.
BunzowJR, SondersMS, ArttamangkulS, et al.Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol, 2001; 60(6):1181–1188; doi: 10.1124/mol.60.6.1181
43.
ParrottAC. Human psychopharmacology of Ecstasy (MDMA): A review of 15 years of empirical research. Hum Psychopharmacol Clin Exp, 2001; 16(8):557–577; doi: 10.1002/hup.351
44.
WimalasenaK. Vesicular monoamine transporters: Structure-function, pharmacology, and medicinal chemistry. Med Res Rev, 2011; 31(4):483–519; doi: 10.1002/med.20187
45.
YaffeD, ForrestLR, SchuldinerS. The ins and outs of vesicular monoamine transporters. J Gen Physiol, 2018; 150(5):671–682; doi: 10.1085/jgp.201711980
46.
LinZ, CanalesJJ, BjörgvinssonT, et al.Chapter 1 monoamine transporters vulnerable and vital doorkeepers. Prog Mol Biol Transl, 2011; 98:1–46; doi: 10.1016/b978-0-12-385506-0.00001-6
47.
ChengMH, BaharI. Monoamine transporters: Structure, intrinsic dynamics and allosteric regulation. Nat Struct Mol Biol, 2019; 26(7):545–556; doi: 10.1038/s41594-019-0253-7
48.
EidenLE, WeiheE. VMAT2: A dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci, 2011; 1216(1):86–98; doi: 10.1111/j.1749-6632.2010.05906.x
VerricoCD, MillerGM, MadrasBK. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: Implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology, 2007; 189(4):489–503; doi: 10.1007/s00213-005-0174-5
51.
DunlapLE, AndrewsAM, OlsonDE. Dark classics in chemical neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chem Neurosci, 2018; 9(10):2408–2427; doi: 10.1021/acschemneuro.8b00155
52.
SimmlerL, BuserT, DonzelliM, et al.Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol, 2013; 168(2):458–470; doi: 10.1111/j.1476-5381.2012.02145.x
53.
GlennonRA, DukatM. Structure-activity relationships of synthetic cathinones. Curr Top Behav Neurosci, 2016; 32:19–47; doi: 10.1007/7854_2016_41
54.
YangF, FuT, ZhangX, et al.Comparison of computational model and X-ray crystal structure of human serotonin transporter: Potential application for the pharmacology of human monoamine transporters. Mol Simulat, 2017; 43(13–16):1089–1098; doi: 10.1080/08927022.2017.1309653
55.
NavratnaV, GouauxE. Insights into the mechanism and pharmacology of neurotransmitter sodium symporters. Curr Opin Struct Biol, 2019; 54:161–170; doi: 10.1016/j.sbi.2019.03.011
56.
AndersenJ, Stuhr-HansenN, ZachariassenL, et al.Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters. Proc Natl Acad Sci U S A, 2011; 108(29):12137–12142; doi: 10.1073/pnas.1103060108
57.
XueW, FuT, ZhengG, et al.Recent advances and challenges of the drugs acting on monoamine transporters. Curr Med Chem, 2018; 27(23):3830–3876; doi: 10.2174/0929867325666181009123218
58.
Islas ÁA, MorenoLG, SciorT. Induced fit, ensemble binding space docking and Monte Carlo simulations of MDMA ‘ecstasy’ and 3D pharmacophore design of MDMA derivatives on the human serotonin transporter (hSERT). Heliyon, 2021; 7(8):e07784; doi: 10.1016/j.heliyon.2021.e07784
59.
YangD, GouauxE. Illumination of serotonin transporter mechanism and role of the allosteric site. Sci Adv, 2021; 7(49):eabl3857; doi: 10.1126/sciadv.abl3857
PenmatsaA, WangKH, GouauxE. X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol, 2015; 22(6):506–508; doi: 10.1038/nsmb.3029
62.
WangKH, PenmatsaA, GouauxE. Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature, 2015; 521(7552):322–327; doi: 10.1038/nature14431
63.
SetolaV, HufeisenSJ, Grande-AllenKJ, et al.3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol, 2003; 63(6):1223–1229; doi: 10.1124/mol.63.6.1223
64.
HuotP, JohnstonTH, LewisKD, et al.Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of on-time. J Neurosci, 2011; 31(19):7190–7198; doi: 10.1523/jneurosci.1171-11.2011
65.
JohnsonMP, HoffmanAJ, NicholsDE. Effects of enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol, 1986; 132(2–3):269–276; doi: 10.1016/0014-2999(86)90615-1
66.
PittsEG, CurryDW, HampshireKN, et al.(±)-MDMA and its enantiomers: Potential therapeutic advantages of R(−)-MDMA. Psychopharmacology, 2018; 235(2):377–392; doi: 10.1007/s00213-017-4812-5
67.
FantegrossiWE. In vivo pharmacology of MDMA and its enantiomers in Rhesus monkeys. Exp Clin Psychopharm, 2008; 16(1):1–12; doi: 10.1037/1064-1297.16.1.1
68.
MurnaneKS, MuraiN, HowellLL, et al.Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(−)-MDMA trained mice. J Pharmacol Exp Ther, 2009; 331(2):717–723; doi: 10.1124/jpet.109.156174
69.
MurnaneKS, FantegrossiWE, GodfreyJR, et al.Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in Rhesus monkeys. J Pharmacol Exp Ther, 2010; 334(2):642–650; doi: 10.1124/jpet.110.166595
70.
HysekC, SimmlerL, IneichenM, et al.The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“Ecstasy”) in humans. Clin Pharmacol Ther, 2011; 90(2):246–255; doi: 10.1038/clpt.2011.78
71.
HysekCM, SimmlerLD, NicolaVG, et al.Duloxetine inhibits effects of MDMA (“Ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLos One, 2012; 7(5):e36476; doi: 10.1371/journal.pone.0036476
72.
SchmidY, RickliA, SchaffnerA, et al.Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther, 2015; 353(1):102–111; doi: 10.1124/jpet.114.222356
73.
FonsecaDA, RibeiroDM, TapadasM, et al.Ecstasy (3,4-methylenedioxymethamphetamine): Cardiovascular effects and mechanisms. Eur J Pharmacol, 2021; 903:174156; doi: 10.1016/j.ejphar.2021.174156
74.
LiechtiME. Effects of MDMA on body temperature in humans. Temp Multidiscip Biomed J, 2014; 1(3):192–200; doi: 10.4161/23328940.2014.955433
WangY, LinW, WuN, et al.Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis. Acta Pharmacol Sin, 2019; 40(9):1138–1156; doi: 10.1038/s41401-019-0217-9
77.
AdayevT, RanasingheB, BanerjeeP. Transmembrane signaling in the brain by serotonin, a key regulator of physiology and emotion. Biosci Rep, 2005; 25(5–6):363–385; doi: 10.1007/s10540-005-2896-3
78.
BarnesNM, SharpT. A review of central 5-HT receptors and their function. Neuropharmacology, 1999; 38(8):1083–1152; doi: 10.1016/s0028-3908(99)00010-6
79.
EshlemanAJ, WolfrumKM, HatfieldMG, et al.Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol, 2013; 85(12):1803–1815; doi: 10.1016/j.bcp.2013.04.004
80.
RickliA, MoningOD, HoenerMC, et al.Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharm, 2016; 26(8):1327–1337; doi: 10.1016/j.euroneuro.2016.05.001
81.
TetteyJNA, CreanC, IfeagwuSC, et al.Emergence, diversity, and control of new psychoactive substances: A global perspective. Handb Exp Pharmacol, 2018; 252:51–67; doi: 10.1007/164_2018_127
82.
SadzotB, BarabanJM, GlennonRA, et al.Hallucinogenic drug interactions at human brain 5-HT2 receptors: Implications for treating LSD-induced hallucinogenesis. Psychopharmacology, 1989; 98(4):495–499; doi: 10.1007/bf00441948
83.
KehneJ, KettelerH, McCloskeyT, et al.Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology, 1996; 15(2):116–124; doi: 10.1016/0893-133x(95)00160-f
84.
LiechtiME, SaurMR, GammaA, et al.Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology, 2000; 23(4):396–404; doi: 10.1016/s0893-133x(00)00126-3
85.
SchmidtCJ, SullivanCK, FedayalGM. Blockade of striatal 5-hydroxytryptmine2 receptors reduces the increase in extracellullar concentrations of dopamine produced by the amphhetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem, 1994; 62(4):1382–1389; doi: 10.1046/j.1471-4159.1994.62041382.x
86.
NicholsDE. Entactogens: How the name for a novel class of psychoactive agents originated. Front Psychiatry, 2022; 13:863088; doi: 10.3389/fpsyt.2022.863088
87.
NashJF, RothBL, BrodkinJD, et al.Effect of the R(−) and S(+) isomers of MDA and MDMA on phosphotidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett, 1994; 177(1–2):111–115; doi: 10.1016/0304-3940(94)90057-4
88.
OeriHE. Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J Psychopharmacol Oxf Engl, 2021; 35(5):512–536; doi: 10.1177/0269881120920420
89.
WiseRA, BozarthMA. Brain mechanisms of drug reward and euphoria. Psychiatr Med, 1985; 3(4):445–460.
90.
LindgrenE, GrayK, MillerG, et al.Food addiction A common neurobiological mechanism with drug abuse. Front Biosci, 2018; 23(3):811–836; doi: 10.2741/4618
91.
HellbergSN, RussellTI, RobinsonMJF. Cued for risk: Evidence for an incentive sensitization framework to explain the interplay between stress and anxiety, substance abuse, and reward uncertainty in disordered gambling behavior. Cogn Affect Behav Neurosci, 2019; 19(3):737–758; doi: 10.3758/s13415-018-00662-3
92.
GoldLH, HubnerCB, KoobGF. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology, 1989; 99(1):40–47; doi: 10.1007/bf00634450
93.
KellandMD, FreemanAS, ChiodoLA. (±)-3,4-Methylenedioxymethamphetamine-induced changes in the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons. Eur J Pharmacol, 1989; 169(1):11–21; doi: 10.1016/0014-2999(89)90812-1
94.
MartelJC, McArthurSG. Dopamine receptor subtypes, physiology and pharmacology: New ligands and concepts in schizophrenia. Front Pharmacol, 2020; 11:1003; doi: 10.3389/fphar.2020.01003
95.
SantilloMF. Inhibition of monoamine oxidase (MAO) by α-ethylphenethylamine and N,α-diethylphenethylamine, two compounds related to dietary supplements. Food Chem Toxicol, 2014; 74:265–269; doi: 10.1016/j.fct.2014.10.009
96.
CarvalhoM, CarmoH, CostaVM, et al.Toxicity of amphetamines: An update. Arch Toxicol, 2012; 86(8):1167–1231; doi: 10.1007/s00204-012-0815-5
97.
RisbroughVB, MastenVL, CaldwellS, et al.Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology, 2006; 31(11):2349–2358; doi: 10.1038/sj.npp.1301161
98.
VerricoCD, LynchL, FaheyMA, et al.MDMA-induced impairment in primates: Antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. J Psychopharmacol, 2008; 22(2):187–202; doi: 10.1177/0269881107083639
99.
LiechtiME, BaumannC, GammaA, et al.Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology, 2000; 22(5):513–521; doi: 10.1016/s0893-133x(99)00148-7
100.
FantegrossiWE, UllrichT, RiceKC, et al.3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) and its stereoisomers as reinforcers in rhesus monkeys: Serotonergic involvement. Psychopharmacology, 2002; 161(4):356–364; doi: 10.1007/s00213-002-1021-6
101.
HiramatsuM, ChoAK. Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: An in vivo microdialysis study. Neuropharmacology, 1990; 29(3):269–275; doi: 10.1016/0028-3908(90)90012-g
102.
SteeleTD, NicholsDE, YimGKW. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol, 1987; 36(14):2297–2303; doi: 10.1016/0006-2952(87)90594-6
103.
InserraA, GregorioDD, GobbiG. Psychedelics in psychiatry: Neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev, 2021; 73(1):202–277; doi: 10.1124/pharmrev.120.000056
104.
BerridgeCW, WaterhouseBD. The locus coeruleus–Noradrenergic system: Modulation of behavioral state and state-dependent cognitive processes. Brain Res Rev, 2003; 42(1):33–84; doi: 10.1016/s0165-0173(03)00143-7
105.
HowellsFM, SteinDJ, RussellVA. Synergistic tonic and phasic activity of the locus coeruleus norepinephrine (LC-NE) arousal system is required for optimal attentional performance. Metab Brain Dis, 2012; 27(3):267–274; doi: 10.1007/s11011-012-9287-9
106.
TimmermansPBMWM, ZwietenPAV. alpha.2 Adrenoceptors: Classification, localization, mechanisms and targets for drugs. J Med Chem, 1982; 25(12):1389–1401; doi: 10.1021/jm00354a001
107.
HysekCM, VollenweiderFX, LiechtiME. Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy). Emerg Med J, 2010; 27(8):586; doi: 10.1136/emj.2009.079905
108.
HysekC, SchmidY, RickliA, et al.Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Carvedilol and MDMA. Br J Pharmacol, 2012; 166(8):2277–2288; doi: 10.1111/j.1476-5381.2012.01936.x
109.
HysekCM, BruggerR, SimmlerLD, et al.Effects of the α2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther, 2012; 340(2):286–294; doi: 10.1124/jpet.111.188425
110.
BexisS, DochertyJR. Role of α 1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse: MDMA, α 1-adrenoceptors and body temperature. Br J Pharmacol, 2008; 153(3):591–597; doi: 10.1038/sj.bjp.0707590
111.
BexisS, DochertyJR. Role of alpha2A-adrenoceptors in the effects of MDMA on body temperature in the mouse. Br J Pharmacol, 2005; 146(1):1–6; doi: 10.1038/sj.bjp.0706320
112.
CapelaJP, CarmoH, RemiãoF, et al.Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: An overview. Mol Neurobiol, 2009; 39(3):210–271; doi: 10.1007/s12035-009-8064-1
113.
BenedettiMS. Biotransformation of xenobiotics by amine oxidases. Fundam Clin Pharm, 2001; 15(2):75–84; doi: 10.1046/j.1472-8206.2001.00011.x
114.
ShalabyR, PetzerJP, PetzerA, et al.SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs. J Enzyme Inhib Med Chem, 2019; 34(1):863–876; doi: 10.1080/14756366.2019.1593158
115.
TripathiAC, UpadhyayS, PaliwalS, et al.Privileged scaffolds as MAO inhibitors: Retrospect and prospects. Eur J Med Chem, 2018; 145:445–497; doi: 10.1016/j.ejmech.2018.01.003
116.
Vilches-HerreraM, Miranda-SepúlvedaJ, Rebolledo-FuentesM, et al.Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorgan Med Chem, 2009; 17(6):2452–2460; doi: 10.1016/j.bmc.2009.01.074
117.
FresquiMAC, FerreiraMMC, TrsicM. The influence of R and S configurations of a series of amphetamine derivatives on quantitative structure–activity relationship models. Anal Chim Acta, 2013; 759:43–52; doi: 10.1016/j.aca.2012.11.004
118.
Reyes-ParadaM, Iturriaga-VasquezP, CasselsBK. Amphetamine derivatives as monoamine oxidase inhibitors. Front Pharmacol, 2020; 10:1590; doi: 10.3389/fphar.2019.01590
119.
LeonardiETK, AzmitiaEC. MDMA (Ecstasy) Inhibition of MAO type A and type B: Comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology, 1994; 10(4):231–238; doi: 10.1038/npp.1994.26
120.
BrownCM, ReisfeldB, MayenoAN. Cytochromes P450: A structure-based summary of biotransformations using representative substrates. Drug Metab Rev, 2008; 40(1):1–100; doi: 10.1080/03602530701836662
121.
NelsonDR. Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed Edited by Paul R. Ortiz de Montellano (University of California, San Francisco). Kluwer Academic/Plenum Publishers: New York. 2005. xx +690 pp. $149.00. ISBN 0-306-48324-6. J Am Chem Soc, 2005; 127(34):12147–12148; doi: 10.1021/ja041050x
122.
MaurerHH, Bickeboeller-FriedrichJ, KraemerT, et al.Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’). Toxicol Lett, 2000; 112:133–142; doi: 10.1016/s0378-4274(99)00207-6
123.
SchindlerCW, ThorndikeEB, BloughBE, et al.Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. Br J Pharmacol, 2013; 171(1):83–91; doi: 10.1111/bph.12423
124.
SwamiT, WeberHC. Updates on the biology of serotonin and tryptophan hydroxylase. Curr Opin Endocrinol Diabetes Obes, 2018; 25(1):12–21; doi: 10.1097/med.0000000000000383
125.
BonkaleWL, AustinMC. 3,4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleus. Neuroscience, 2008; 155(1):270–276; doi: 10.1016/j.neuroscience.2008.03.086
126.
EastonN, MarsdenCA. Ecstasy: Are animal data consistent between species and can they translate to humans?. J Psychopharmacol, 2006; 20(2):194–210; doi: 10.1177/0269881106061153
127.
StoneDM, JohnsonM, HansonGR, et al.Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur J Pharmacol Mol Pharmacol, 1989; 172(1):93–97; doi: 10.1016/0922-4106(89)90048-5
128.
CostaG, GołembiowskaK. Neurotoxicity of MDMA: Main effects and mechanisms. Exp Neurol, 2022; 347:113894; doi: 10.1016/j.expneurol.2021.113894
129.
BiezonskiDK, MeyerJS. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: Implications for MDMA neurotoxicity. J Neurochem, 2010; 112(4):951–962; doi: 10.1111/j.1471-4159.2009.06515.x
130.
MolliverME, BergerUV, MamounasLA, et al.Neurotoxicity of MDMA and related compounds: Anatomic studies. Ann N Y Acad Sci, 1990; 600(1 The Neurophar):649–661; discussion 661–4; doi: 10.1111/j.1749-6632.1990.tb16916.x
131.
SOUZAEB, BATTAGLIAG, INSELTR. Neurotoxic effects of MDMA on brain serotonin neurons: Evidence from neurochemical and radioligand binding studies. Ann N Y Acad Sci, 1990; 600(1 The Neurophar):682–697; doi: 10.1111/j.1749-6632.1990.tb16918.x
132.
TeitlerM, LeonhardtS, AppelNM, et al.Receptor pharmacology of MDMA and related hallucinogens. Ann N Y Acad Sci, 1990; 600(1 The Neurophar):626–638; doi: 10.1111/j.1749-6632.1990.tb16915.x
133.
GrossmanMH, EmanuelBS, BudarfML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1→q11.2. Genomics, 1992; 12(4):822–825; doi: 10.1016/0888-7543(92)90316-k
134.
CarmoH, BrulportM, HermesM, et al.Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (‘Ecstasy’) cytotoxicity. Pharmacogenet Genomics, 2006; 16(11):789–799; doi: 10.1097/01.fpc.0000230419.05221.fc
135.
Pardo-LozanoR, FarréM, Yubero-LahozS, et al.Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”): The influence of gender and genetics (CYP2D6, COMT, 5-HTT). PLos One, 2012; 7(10):e47599; doi: 10.1371/journal.pone.0047599
StokesAH, HastingsTG, VranaKE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res, 1999; 55(6):659–665; doi: 10.1002/(sici)1097-4547(19990315)55:6<659::aid-jnr1>3.0.co;2-c
138.
HeutherG, ReimerA, SchmidtF, et al.Oxidation of the indole nucleus of 5-hydroxytryptamine and formation of dimers in the presence of peroxidase and H2O2. J Neural Transm Suppl, 1990; 32:249–257; doi: 10.1007/978-3-7091-9113-2_35
139.
QuintonMS, YamamotoBK. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J, 2006; 8(2):E337–E337; doi: 10.1007/bf02854904
140.
CurryDW, YoungMB, TranAN, et al.Separating the agony from ecstasy: R(–)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice. Neuropharmacology, 2018; 128:196–206; doi: 10.1016/j.neuropharm.2017.10.003
141.
ColeJC, SumnallHR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev, 2003; 27(3):199–217; doi: 10.1016/s0149-7634(03)00031-9
142.
JîtcăG, ŐszBE, Tero-VescanA, et al.Psychoactive drugs—From chemical structure to oxidative stress related to dopaminergic neurotransmission. A review. Antioxidants, 2021; 10(3):381; doi: 10.3390/antiox10030381
143.
Anonymous. Pharmacology and toxicology of amphetamine and related designer drugs. NIDA Res Monogr, 1989; 94:1–357.
144.
Martínez-ClementeJ, López-ArnauR, CarbóM, et al.Mephedrone pharmacokinetics after intravenous and oral administration in rats: Relation to pharmacodynamics. Psychopharmacology, 2013; 229(2):295–306; doi: 10.1007/s00213-013-3108-7
ShulginAT. Psychotomimetic agents related to mescaline. Experientia, 1963; 19(3):127–128; doi: 10.1007/bf02171586
147.
WinterJC. Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus. Psychopharmacology, 1980; 68(2):159–162; doi: 10.1007/bf00432134
148.
AertsLAGJM, MallaretM, RigterH. N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): Its properties and possible risks. Addict Biol, 2000; 5(3):269–282; doi: 10.1111/j.1369-1600.2000.tb00191.x
149.
VizeliP, LiechtiME. Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects. PLos One, 2018; 13(6):e0199384; doi: 10.1371/journal.pone.0199384
150.
LiechtiME, GammaA, VollenweiderFX. Gender differences in the subjective effects of MDMA. Psychopharmacology, 2001; 154(2):161–168; doi: 10.1007/s002130000648
151.
PapaseitE, TorrensM, Pérez-MañáC, et al.Key interindividual determinants in MDMA pharmacodynamics. Expert Opin Drug Met, 2018; 14(2):183–195; doi: 10.1080/17425255.2018.1424832
152.
VizeliP, LiechtiME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol, 2017; 31(5):576–588; doi: 10.1177/0269881117691569
153.
VizeliP, SchmidY, PrestinK, et al.Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur Neuropsychopharm, 2017; 27(3):232–238; doi: 10.1016/j.euroneuro.2017.01.008
154.
MillerDB, O'CallaghanJP. The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol Neurobiol, 1995; 11(1–3):177–192; doi: 10.1007/bf02740694
155.
WalkerQD, WilliamsCN, JotwaniRP, et al.Sex differences in the neurochemical and functional effects of MDMA in Sprague–Dawley rats. Psychopharmacology, 2007; 189(4):435–445; doi: 10.1007/s00213-006-0531-z
156.
WyethRP, MillsEM, UllmanA, et al.The hyperthermia mediated by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) is sensitive to sex differences. Toxicol Appl Pharm, 2009; 235(1):33–38; doi: 10.1016/j.taap.2008.12.003
157.
WallingaAE, GrahlmannC, GrannemanRA, et al.Gender differences in hyperthermia and regional 5-HT and 5-HIAA depletion in the brain following MDMA administration in rats. Brain Res, 2011; 1398:13–20; doi: 10.1016/j.brainres.2011.04.039
158.
PalenicekT, VotavaM, BubenikovaV, et al.Increased sensitivity to the acute effects of MDMA (“ecstasy”) in female rats. Physiol Behav, 2005; 86(4):546–553; doi: 10.1016/j.physbeh.2005.08.043
159.
KoenigJ, LazarusC, JeltschH, et al.MDMA (ecstasy) effects in pubescent rats: Males are more sensitive than females. Pharmacol Biochem Be, 2005; 81(3):635–644; doi: 10.1016/j.pbb.2005.04.014
160.
LazenkaMF, SuyamaJA, BauerCT, et al.Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol Biochem Be, 2017; 152:52–60; doi: 10.1016/j.pbb.2016.08.004
161.
AslSS, MehdizadehM, ShahrakiSH, et al.Sex differences in MDMA-induced toxicity in Sprague-Dawley rats. Funct Neurol, 2015; 30(2):131–137; doi: 10.11138/fneur/2015.30.2.131
162.
FonsartJ, MenetM-C, DeclèvesX, et al.Sprague–Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Toxicol Appl Pharm, 2008; 230(1):117–125; doi: 10.1016/j.taap.2008.02.004
163.
FonsartJ, MenetM-C, DebrayM, et al.Sprague–Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA). Toxicol Appl Pharm, 2009; 241(3):339–347; doi: 10.1016/j.taap.2009.09.008
164.
DiCarloGE, MabrySJ, CaoX, et al.Autism-associated variant in the SLC6A3 gene alters the oral microbiome and metabolism in a murine model. Front Psychiatry, 2021; 12:655451; doi: 10.3389/fpsyt.2021.655451
165.
VizeliP, LiechtiME. No influence of dopamine system gene variations on acute effects of MDMA. Front Psychiatry, 2019; 10:755; doi: 10.3389/fpsyt.2019.00755
166.
DanforthAL, StrubleCM, Yazar-KlosinskiB, et al.MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry, 2016; 64:237–249; doi: 10.1016/j.pnpbp.2015.03.011
167.
DanforthAL, GrobCS, StrubleC, et al.Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 2018; 235(11):3137–3148; doi: 10.1007/s00213-018-5010-9
168.
BlaxillM, RogersT, NevisonC. Autism Tsunami: The impact of rising prevalence on the societal cost of autism in the United States. J Autism Dev Disord, 2022; 52(6):2627–2643; doi: 10.1007/s10803-021-05120-7
169.
TraynorJM, RobertsDE, RossS, et al.MDMA-assisted psychotherapy for borderline personality disorder. Focus, 2022; 20(4):358–367; doi: 10.1176/appi.focus.20220056
170.
SessaB, HigbedL, NuttD. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychiatry, 2019; 10:138; doi: 10.3389/fpsyt.2019.00138
171.
WolfsonPE, AndriesJ, FeducciaAA, et al.MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Sci Rep, 2020; 10(1):20442; doi: 10.1038/s41598-020-75706-1
172.
FantegrossiWE. In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys.: EBSCOhost. Exp Clin Psychopharmacol, 2008; 16(1):1–12; doi: 10.1037/1064-1297.16.1.1
173.
PantoniMM, AnagnostarasSG. Cognitive effects of MDMA in laboratory animals: A systematic review focusing on dose. Pharmacol Rev, 2019; 71(3):413–449; doi: 10.1124/pr.118.017087
174.
FantegrossiWE, GodlewskiT, KarabenickRL, et al.Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology, 2003; 166(3):202–211; doi: 10.1007/s00213-002-1261-5
175.
FantegrossiWE, KiesselCL, GarzaRDL, et al.Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology, 2005; 181(3):529–536; doi: 10.1007/s00213-005-0005-8
176.
AmelnNV, Ameln-MayerhoferAV. Preclinical study: Atypical development of behavioural sensitization to 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) in adolescent rats and its expression in adulthood: Role of the MDMA chirality. Addict Biol, 2010; 15(1):35–44; doi: 10.1111/j.1369-1600.2009.00187.x
